Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
2024 Readers' Choice Awards
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
LAST CHANCE AUCTION
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Invivyd
< Previous
1
2
Next >
Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2
May 27, 2025
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas
May 23, 2025
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19
May 21, 2025
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights
May 15, 2025
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy
May 14, 2025
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
May 13, 2025
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles
May 12, 2025
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025
May 08, 2025
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank
April 21, 2025
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors
March 26, 2025
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights
March 20, 2025
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1
March 05, 2025
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
FDA Declined Invivyd’s Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing
February 24, 2025
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025
February 10, 2025
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold
February 05, 2025
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population
February 03, 2025
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability
February 03, 2025
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised
January 27, 2025
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC
January 10, 2025
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 14, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor
November 14, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to
November 12, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference
November 06, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024
November 06, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability
October 29, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants
October 29, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024
October 16, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data
October 01, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)
September 23, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19
September 12, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.